This Phase 1 clinical trial is investigating a personalised T-cell therapy called IMA203 (also known as anzutresgene autoleucel) for people with advanced solid tumours, including metastatic uveal melanoma. IMA203 is a type of immunotherapy designed to genetically modify a patient’s own immune cells (T cells) so they can better recognise and attack cancer cells carrying a protein called PRAME, which is commonly found in uveal melanoma. To take part, patients must also have a specific tissue type called HLA-A*02:01.
The study is assessing the safety, tolerability, and effectiveness of IMA203 both on its own and in combination with nivolumab, an immunotherapy drug already used to treat several cancers. Participants undergo a process called leukapheresis, where white blood cells are collected and modified in a laboratory before being infused back into the body. Prior to receiving the treatment, patients also receive chemotherapy to prepare the immune system. Researchers are monitoring side effects, tumour response, and how long the treatment can control the cancer.
Early results presented from the uveal melanoma cohort have shown encouraging anti-tumour activity in some heavily pre-treated patients, including tumour shrinkage and durable responses. Researchers are continuing to expand the study to better understand the long-term benefits and safety of this treatment approach.
At the present time, there are no active UK locations listed for this trial (NCT03686124). Current recruitment appears to be focused on sites in the United States and Germany, and we are not currently aware of any plans for the study to open at UK sites.